Summary of Key Takeaways from the JPM China Opportunity Forum Industry Overview - **Industry**: Healthcare - **Event**: JPM China Opportunity Forum held on January 21-22 Core Company Insights Hansoh Pharma - **Revenue Growth**: Innovative drugs are projected to drive total revenue growth, with their share expected to exceed 80% by FY25 [4] - **Product Pipeline**: Management aims to launch over 20 innovative medicines with more than 40 approved indications by 2030, indicating a sustainable growth trajectory [4] - **Key Product**: Almonertinib (AMEILE) is anticipated to contribute over 50% of innovative drug revenue by 2025, with peak sales estimates raised to RMB 8 billion by 2030 [4] - **Clinical Focus**: The 2026 strategy includes promoting newly approved adjuvant therapy and chemotherapy combinations for first-line non-small cell lung cancer (NSCLC), despite no inclusion in the National Reimbursement Drug List (NRDL) [4] Duality (Not Covered) - **Upcoming Events**: Key data updates expected from DB-1311 (B7H3) in late February, with additional readouts planned for 2026 [4] - **Financial Expectations**: Management anticipates milestone inflows of approximately USD 200 million in 2025-26 [4] - **Strategic Focus**: The company emphasizes a combo-first strategy and differentiated attributes of its antibody-drug conjugate (ADC) platform [4] Aier Eye - **Operational Normalization**: Management noted a gradual normalization in core operations, with average selling prices (ASP) stabilizing and selective demand recovery shaping the 2026 outlook [4] - **Cataract Market**: ASPs for cataracts decreased by approximately 7-8% year-over-year in the first nine months of 2025, with no immediate recovery expected [4] - **Self-Pay Growth**: Self-pay premium offerings, such as femtosecond cataract procedures, showed strong growth of over 20% year-over-year in 9M25 [5] Shenzhen New Industries (Not Covered) - **Growth Projections**: Management expects domestic revenue growth of 5-10% and overseas growth of 20-25% in 2026, driven by market share gains [5] - **ASP Erosion**: The guidance assumes only modest further ASP erosion, with expectations of a decline of less than 5% [5] - **Key Growth Drivers**: Continued share capture in tertiary-hospital replacements and integrated automation line deployments are highlighted as key growth drivers [5] Additional Insights - **Market Conditions**: The overall industry is facing pressure from domestic demand weakness tied to controlled medical insurance expense budgets, impacting test volumes [5] - **Overseas Operations**: Overseas markets, particularly in Europe, are expected to contribute positively to revenue growth, with a projected share of over 12% in FY25 [5] This summary encapsulates the critical insights and projections from the JPM China Opportunity Forum, focusing on the healthcare sector and specific companies within it.